Baseline patient demographics and characteristics
| Characteristic | All patients | ICB-naïve | ICB-experienced | ||
| UBC | MEL | NSCLC | UBC | ||
| N=221 | N=41 | N=18 | N=40 | N=12 | |
| Sex, n (%) | |||||
| Male | 144 (65.2) | 32 (78.0) | 12 (66.7) | 31 (77.5) | 10 (83.3) |
| Female | 77 (34.8) | 9 (22.0) | 6 (33.3) | 9 (22.5) | 2 (16.7) |
| Age (years), median (range) | 62 (18–86) | 67.0 (49–83) | 60 (36–83) | 63 (29–80) | 66 (59–86) |
| ECOG score at baseline, n (%) | |||||
| 0 | 101 (45.7) | 20 (48.8) | 10 (55.6) | 17 (42.5) | 7 (58.3) |
| 1 | 116 (52.5) | 21 (51.2) | 8 (44.4) | 23 (57.5) | 5 (41.7) |
| 2 | 2 (0.9) | 0 | 0 | 0 | 0 |
| Median LDH at baseline (range, U/L) | 224 (93, 8147) | 207 (113, 8147) | 284 (134, 3515) | 246 (155, 754) | 196 (118, 391) |
| Patients with liver metastases, n (%) | 87 (39.4) | 14 (34.1) | 8 (44.4) | 7 (17.5) | 4 (33.3) |
| Patients’ PD-L1 IHC status from available tumor tissue | 34 | 14 | 23 | 9 | |
| IC | |||||
| 0 | – | 29 (85.3) | 6 (42.9) | 10 (43.5) | 2 (22.2) |
| 1 | – | 5 (14.7) | 3 (21.4) | 7 (30.4) | 4 (44.4) |
| 2 | – | 0 | 2 (14.3) | 3 (13.0) | 1 (11.1) |
| 3 | – | 0 | 0 | 3 (13.0) | 0 |
| NA | – | 0 | 3 (21.4) | 0 | 2 (22.2) |
| TC | |||||
| 0 | – | 29 (85.3) | 7 (50.0) | 12 (52.2) | 5 (55.6) |
| 1 | – | 3 (8.8) | 2 (14.3) | 3 (13.0) | 1 (11.1) |
| 2 | – | 2 (5.9) | 2 (14.3) | 6 (26.1) | 1 (11.1) |
| 3 | – | 0 | 0 | 2 (8.7) | 0 |
| NA | – | 0 | 3 (21.4) | 0 | 2 (22.2) |
| Prior anti-cancer therapy lines median no (range) | 3 (0–10) | 2 (1– 6) | 2 (1–7) | 2 (1–9) | 2 (1–5) |
| Duration of prior immunotherapy, median and range (days) | – | – | 98 (35–807) | 126 (14–854) | 102 (48–634) |
| Time from prior immunotherapy to study treatment, median and range (days) | – | – | 182.5 (82–911) | 205 (89–902) | 168 (97–698) |
| ORR to prior immunotherapy, n (%) | 0 | 6 (15.0)* | 4 (33.3)† | ||
| Prior surgery, n (%) | 194 (87.8) | 38 (95.0) | 16 (88.9) | 24 (60.0) | 12 (100) |
| Prior radiotherapy | 96 (43.4) | 13 (32.5) | 9 (50.0) | 22 (55.0) | 3 (25.0) |
| Tumor type, n (%) | |||||
| Urothelial bladder cancer | 67 (30.3) | 41 (100) | – | – | 12 (100) |
| Non-small cell lung cancer | 41 (18.6) | – | – | 40 (100) | – |
| Gastric cancer | 20 (9.0) | – | – | – | – |
| Melanoma | 18 (8.1) | – | 18 (100) | – | – |
| Ovarian cancer | 17 (7.7) | – | – | – | – |
| Soft tissue sarcoma | 17 (7.7) | – | – | – | – |
| Triple-negative breast cancer | 17 (7.7) | – | – | – | – |
| Other | 13 (5.9) | – | – | – | – |
| Colorectal | 11 (5.0) | – | – | – | – |
| No of cycles of study treatment | |||||
| Atezolizumab, median (range) | 4 (1–68) | 4 (1–52) | 5 (1–21) | 4 (1–29) | 2 (1–44) |
| Emactuzumab, median (range) | 3 (1–68) | 3 (1–52) | 4 (1–18) | 3.5 (1–19) | 2 (1–7) |
*Two patients were not evaluable for prior response.
†One patient was not evaluable for prior response.
ECOG, Eastern Cooperative Oncology Group; IC, immune cells; ICB, immune checkpoint blocker; IHC, immunohistochemistry; LDH, lactate dehydrogenase; MEL, melanoma; NA, not applicable; NSCLC, non-small cell lung cancer; ORR, objective response rate; TC, tumor cells; UBC, urothelial bladder cancer.